D
David Miller
Researcher at Graceland University
Publications - 7
Citations - 1106
David Miller is an academic researcher from Graceland University. The author has contributed to research in topics: Addiction & Brain stimulation reward. The author has an hindex of 6, co-authored 7 publications receiving 1026 citations.
Papers
More filters
Journal ArticleDOI
Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.
Kenneth Blum,Eric R. Braverman,Jay M. Holder,Joel F. Lubar,Vincent J. Monastra,David Miller,Judith O. Lubar,Thomas J H Chen,David E. Comings +8 more
TL;DR: In order to explain the breakdown of the reward cascade due to both multiple genes and environmental stimuli (pleiotropism) and resultant aberrant behaviors, Blum united this hypodopaminergic trait under the rubric of a reward deficiency syndrome.
Journal ArticleDOI
Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.
Kenneth Blum,Marlene Oscar-Berman,Elizabeth Stuller,David Miller,John Giordano,Siobhan Morse,Lee McCormick,William B. Downs,Roger L. Waite,Debmalya Barh,Dennis Neal,Eric R. Braverman,Raquel Lohmann,Joan Borsten,Mary Hauser,David K. Han,Yijun Liu,Manya Helman,Thomas Simpatico +18 more
TL;DR: This is a review, with some illustrative case histories from a number of addiction professionals, of certain molecular neurobiological mechanisms which if ignored may lead to clinical complications.
Journal ArticleDOI
Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.
Thomas J H Chen,Kenneth Blum,Amanda L C Chen,Abdalla Bowirrat,William B. Downs,Margret A Madigan,Roger L. Waite,John A. Bailey,Mallory Kerner,Swetha Yeldandi,Neil Majmundar,John Giordano,Siohban Morse,David Miller,Frank Fornari,Eric R Braverman +15 more
TL;DR: Evidence supporting the role of the KB220/KB220Z neuroadaptagens consisting of amino-acid neurotransmitter precursors and enkephalinase-catecholamine–methyl-transferase (COMT) inhibition therapy called Neuroadaptagen Amino Acid Therapy (NAAT) in brain reward function is presented.
Journal ArticleDOI
Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
David Miller,Abdalla Bowirrat,Matthew Manka,Merlene Miller,Stanley Stokes,Debra Manka,Cameron Allen,Charles Gant,B. William Downs,Andrew Smolen,Emily Stevens,Swetha Yeldandi,Kenneth Blum +12 more
TL;DR: It is cautiously suggested that long-term activation of dopaminergic receptors will result in their proliferation and lead to enhanced “dopamine sensitivity” and an increased sense of happiness, particularly in carriers of the DRD2 A1 allele.
Journal ArticleDOI
Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study.
Merlene Miller,Amanda L C Chen,Stan D Stokes,Susan Silverman,Abdalla Bowirrat,Matthew Manka,Debra Manka,David Miller,Kenneth Perrine,Thomas J H Chen,John A. Bailey,William B. Downs,Roger L. Waite,Margaret A. Madigan,Eric R Braverman,Uma Damle,Mallory Kerner,John Giordano,Siobhan Morse,Marlene Oscar-Berman,Debmalya Barh,Kenneth Blum +21 more
TL;DR: A pilot experiment found a significant reduction of chronic symptoms, measured by the Chronic Abstinence Symptom Severity (CASS) Scale, in the combined group (IV and oral) did significantly better than the oral-only group over the first week and 30-day follow-up period.